The strategic partnership agreement between Gnubiotics Sciences and ADM will be centered on the commercialization of innovative microbiome solutions for companion animal health and wellbeing.
Gnubiotics Science has designed a line of functional ingredients and supplement lines designed for immunomodulation, microbiome modulation, and microbiome recovery post-antibiotic use in pets.
The company’s pipeline of microbiome targeted solutions includes products aiming to repair and heal the imbalanced microbiome of companion animals.
Gnubiotics is also working on a diverse set of non-digestible animal milk glycans to support the microbiome, and immune system and strengthen the gut barrier of puppies and kittens at birth.
In 2021, Gnubiotics also announced patents covering microbiome-based markers to predict, diagnose and treat feline obesity, a major cause of diabetes and chronic kidney disease in felines.
Besides the animal glycopeptide pipeline, Gnubiotics is also developing strategies to modulate the human microbiome safely and effectively by selectively promoting the growth of essential commensal microbes and controlling pathogenic microbes.
To improve the human microbiome health, the company is researching how to produce metabolites essential for immune protection and regulating inflammatory responses starting with preclinical research on anti-cancer drugs and anti-inflammatory agents to treat chronic inflammatory diseases such as inflammatory bowel disease.
The collaboration with ADM a premier global human and animal nutrition company will combine cutting-edge technologies to the pipeline of microbiome-focused innovation from Gnubiotics.
ADM works on the power of plant-based products and sustainability solutions to benefit human and animal health. Moreover, the company aims to provide alternatives to the petroleum-based industry, researching industrial bio-solutions and offering a growing portfolio of plant-based materials for agriculture, construction, fermentation, home care, and packaging.
Yemi Adesokan, CEO and Co-Founder, of Gnubiotics said: “We are pleased to work with ADM, a global leader in human and animal health and nutrition. We have developed products that have functional and clinically demonstrated applications for animal health and well-being. This partnership with ADM is a major accomplishment for Gnubiotics as it represents a validation of our science and technology. We are excited to collaborate with ADM to continue developing and bringing to market, data-driven microbiome-targeted solutions.”
ADM said: “We´re excited about this partnership with Gnubiotics, and the capabilities they bring, enabling pet parents to understand their pets’ microbiome better. With this knowledge, ADM can leverage its comprehensive pantry of pet and animal well-being solutions to improve individual pet health through precise nutrition and supplementation.”